前の章|次の章

中医学によるPI3K/Aktシグナル経路調節を介した慢性萎縮性胃炎治療の研究進展

  • role： First author第一作者
  • Affiliation：

    Hubei University of Chinese Medicine，Wuhan 430065，China

  • Email：2718036731@qq.com
  • Introduction：丁毓雪，在读硕士，从事中西医结合治疗消化系统疾病研究，E-mail：2718036731@qq.com
DING Yuxue1,  
  • Affiliation：

    Hubei University of Chinese Medicine，Wuhan 430065，China

SU Zhiwei1,  
  • Affiliation：

    Hubei Provincial Hospital of Integrated Chinese and Western Medicine，Wuhan 430015，China

XUE Juan2,  
  • Affiliation：

    Hubei Provincial Hospital of Integrated Chinese and Western Medicine，Wuhan 430015，China

SUN Jun2,  
  • role： Corresponding author通信作者
  • Affiliation：

    Hubei University of Chinese Medicine，Wuhan 430065，China

    Hubei Provincial Hospital of Integrated Chinese and Western Medicine，Wuhan 430015，China

  • Email：574900945@qq.com
  • Introduction：计春燕，硕士，主任医师，硕士生导师，从事中西医结合治疗消化系统疾病研究，E-mail：574900945@qq.com
JI Chunyan12*

サマリー

慢性萎縮性胃炎（CAG）は、胃粘膜固有腺の数の減少および萎縮を特徴とする消化器系疾患である。その発症はピロリ菌（Hp）感染、長期の不良な食生活や生活習慣などの危険因子と密接に関連している。CAGは胃がんの発症過程における重要な環であり、その悪化を効果的に阻止することは胃がんの予防において重要な意義を持つ。現在の西洋医学的治療は主にHpの根絶、胃粘膜の保護および胃腸の動態促進を目的とした対症療法であるが、長期服用による耐性の発生や腺の萎縮の不可逆的な限界が存在し、新たな介入戦略の模索が急務である。近年、CAGのメカニズム研究の深化とともに、リン脂質3-キナーゼ（PI3K）/プロテインキナーゼB（Akt）シグナル経路は古典的なシグナル経路の一つとしてCAGの発症・進展に顕著な役割を果たすが、体系的な総説はまだ存在しない。中医学は「多標的、多経路、低毒性」といった調節優位性に基づき、PI3K/Akt経路の重要なノード介入を通じてCAGの病理進行を改善できる。本稿は中医学がPI3K/Aktシグナル経路を調節してCAGを改善する研究の進展を初めて体系的に総説し、CAGにおけるPI3K/Aktシグナル経路の発現、炎症および酸化ストレス反応、細胞増殖・アポトーシス・オートファジーの調節などを論じた。この経路を調節するフラボノイド、アルカロイド、テルペン類およびその他の化合物をまとめた。中薬複方は小柴胡湯、半夏瀉心湯などの古典方剤、摩羅丹濃縮丸、莪連顆粒などの中成薬、楽胃飲加減法や芪靈方などの経験方を含む。中医学の優位性を十分に発揮し、CAG治療領域での広範な応用と深い発展の基盤を築き、CAGの臨床研究および医薬品研究に新たな知見を提供することを目的とする。

キーワード

リン脂質3-キナーゼ（PI3K）/プロテインキナーゼB（Akt）シグナル経路;慢性萎縮性胃炎（CAG）;中医学;多標的調節;研究進展

References

  1. 1.
    YUAN Y，HONG L L，NA W，et al.Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020：An updated systematic review and Meta-analysis［J］.Ann Palliat Med，2022，11（12）：3697-3703.
  2. 2.
    ZHOU Z H，LIANG K，CUI B，et al.Traditional Chinese medicine intervenes signaling pathways associated with Hp-negative chronic atrophic gastritis：A review［J］.Chin Arch Tradit Chin Med，2024，42（5）：82-88.
  3. 3.
    LI Y，JIANG F，WU C Y，et al.Prevalence and temporal trend of gastric preneoplastic lesions in Asia：A systematic review with Meta-analysis［J］.United European Gastroenterol J，2024，12（1）：139-151.
  4. 4.
    XU F，NIU L X，LI Y F，et al.Roles of the PI3K/Akt/mTOR signalling pathways in neurodegenerative diseases and tumours［J］.Cell Biosci，2020，10（1）：54.
  5. 5.
    LIU Z L，CAO Y，ZHANG W Z，et al.PI3K/Akt signal pathway：A target of natural products in the prevention and treatment of Alzheimer's disease and Parkinson's disease［J］.Front Pharmacol，2021，12：648636.
  6. 6.
    ACOSTA-MARTINEZ M，CABAIL M Z.The PI3K/Akt pathway in Meta-inflammation［J］.Int J Mol Sci，2022，23（23）：15330.
  7. 7.
    XU M Y，HUANG J，SHEN Z W，et al.Study progress on traditional Chinese medicine monomer intervening in pancreatic cancer by regulating PI3K/Akt signaling pathway［J］.China Pharm，2023，34（19）：2427-2432.
  8. 8.
    ZHU H，CHAN K T，HUANG X，et al.Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation［J］.Elife，2022，11：e71929.
  9. 9.
    WANG T，CHEN C，YANG L，et al.Role of Nrf2/HO-1 signal axis in the mechanisms for oxidative stress-relevant diseases［J］.J Cent South Univ：Med Sci，2019，44（1）：74-80.
  10. 10.
    WANG S，LIU Y，SUN Q，et al.Triple cross-linked dynamic responsive hydrogel loaded with selenium nanoparticles for modulating the inflammatory microenvironment via PI3K/Akt/NF-κB and MAPK signaling pathways［J］.Adv Sci （Weinh），2023，10（31）：e2303167.
  11. 11.
    TANG X，CHEN X，LI X，et al.The TLR4 mediated inflammatory signal pathway might be involved in drug resistance in drug-resistant epileptic rats［J］.J Neuroimmunol，2022，365：577802.
  12. 12.
    LI R，ZOU X，HUANG H，et al.HMGB1/PI3K/Akt/mTOR signaling participates in the pathological process of acute lung injury by regulating the maturation and function of dendritic cells［J］.Front Immunol，2020，11：1104.
  13. 13.
    PAHLAVANI H A.Exercise-induced signaling pathways to counteracting cardiac apoptotic processes［J］.Front Cell Dev Biol，2022，10：950927.
  14. 14.
    LIU S Y，LI K，LAN K，et al.The role of autophagy in the pathogenesis of steroid induced osteonecrosis of the femoral head in rats［J］.Chin J Gerontol，2023，43（4）：896-900.
  15. 15.
    NIU Z Y，SHI Y Y，LI S Z，et al.Characteristics of gastric microbiota in Helicobacter pylori associated chronic gastritis［J］.J Clin Med Pract，2024，28（1）：56-61.
  16. 16.
    WU Q Q，SUN S，YAN F Q，et al.Protective effect of baicalin regulating PI3K/Akt pathway on hydrogen peroxide induced endothelial progenitor cell injury［J］.Chin J Gerontol，2024，44（5）：1230-1236.
  17. 17.
    TANG S，DENG X，ZHOU J，et al.Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects［J］.Biomed Pharmacother，2020，121：109604.
  18. 18.
    SHEN H，ZHANG X，MA Y L，et al.Eriodictyol suppresses gastric cancer cells via inhibition of PI3K/Akt pathway［J］.Pharmaceuticals，2022，15（12）：1477.
  19. 19.
    ROCCHETTI M T，BELLANTI F，ZADOROZHNA M，et al.Multi-faceted role of luteolin in cancer metastasis：EMT，angiogenesis，ECM degradation and apoptosis［J］.Int J Mol Sci，2023，24（10）：8824.
  20. 20.
    WEN Q，LI Y，WANG C J.Exploring the mechanism of action treating chronic atrophic gastritis with Zuai Weitai based on network pharmacology and molecular docking［J］.Clin J Chin Med，2021，13（32）：22-27.
  21. 21.
    XU W H，REDDY K A，KATO K，et al.In vivo profiling of a natural alkaloid，anatabine，in rodents：Pharmacokinetics and anti-inflammatory efficacy［J］.J Nat Prod，2021，84（4）：1012-1021.
  22. 22.
    SHAKERI F，KIANI S，RAHIMI G，et al.Anti-inflammatory，antioxidant，and immunomodulatory effects of Berberis vulgaris and its constituent berberine，experimental and clinical，a review［J］.Phytother Res，2024，38（4）：1882-1902.
  23. 23.
    TU Y L，LI L P，WANG R L，et al.Berberine attenuates chronic atrophic gastritis induced by MNNG and its potential mechanism［J］.Front Pharmacol，2021，12：644638.
  24. 24.
    FAN J H.The mechanism of coptisine inhibiting the proliferation and metastasis of hepatocellular carcinoma by promoting the ubiquitination of IGF2BP1［D］.Chongqing：Southwest University，2022.
  25. 25.
    TAN L H.Coptisine and epiberberine，the characteristic constituents of Rhizoma Coptidis，inhibit Helicobacter pylori：Susceptibility and mechanism［D］.Guangzhou：Guangzhou University of Chinese Medicine，2019.
  26. 26.
    WANG J，DU P L，DONG J Q，et al.Effect of coptisine on PI3K/Akt/mTOR signaling pathway in chronic atrophic gastritis rats［J］.Chin J Exp Tradit Med Form，2024，30（18）：117-124.
  27. 27.
    GUO Y J，SHANG L J，LI R，et al.Advances in pharmacological activities of terpenoids［J］.Nat Prod Commun，2020，15（3）：1934578X-20903555X.
  28. 28.
    GUO Y J，SHANG L J，LI R，et al.Pachymic acid inhibits inflammation and cell apoptosis in lipopolysaccharide （LPS）-induced rat model with pneumonia by regulating NF-κB and MAPK pathways［J］.Allergol Immunopathol （Madr），2021，49（5）：87-93.
  29. 29.
    XU L，ZHANG D Y，WANG R F.Therapeutic effect of pachymie acid on Helicobacter pylori-associatedgastritis in rats by regulating the PI3K/Akt/NF-κB signaling pathway［J］.Basic Clin Med，2024，44（4）：489-495.
  30. 30.
    JIN W，LI C，YANG S，et al.Hypolipidemic effect and molecular mechanism of ginsenosides：A review based on oxidative stress［J］.Front Pharmacol，2023，14：1166898.
  31. 31.
    LIU W，PAN H，YANG L，et al.Panax ginseng C.A.Meyer （Rg3） ameliorates gastric precancerous lesions in Atp4a-/- mice via inhibition of glycolysis through PI3K/Akt/miRNA-21 pathway［J］.Evid Based Complement Alternat Med，2020，2020：2672648.
  32. 32.
    WANG S，LI Z，MA Y，et al.Immunomodulatory effects of green tea polyphenols［J］.Molecules，2021，26（12）：3755.
  33. 33.
    ZHANG F Y，XIAO Y L，PAN J L，et al.Epigallocatechin gallate protects against MNNG-induced precancerous lesions of gastric carcinoma in rats via PI3K/Akt/mTOR pathway［J］.Evid Based Complement Alternat Med，2021，2021：8846813.
  34. 34.
    WANG Y，CHEN F H，LI J，et al.Erianin，the main active ingredient of Dendrobium chrysotoxum Lindl，inhibits precancerous lesions of gastric cancer （PLGC） through suppression of the HRAS-PI3K-Akt signaling pathway as revealed by network pharmacology and in vitro experimental verification［J］.J Ethnopharmacol，2021，279：114399.
  35. 35.
    QIN B J，CHEN Y Q，GONG W H，et al.Explore the prescription law and mechanism of CHEN Guozhong in the treatment of chronic atrophic gastritis based on data integration research and virtual drug target［J］.Tradit Chin Drug Res Clin Pharmacol，2022，33（2）：201-210.
  36. 36.
    LI M J，LU G H.Overview of the mechanism of action of Xiaochaihu decoction in digestive system diseases［J］.J Pract Tradit Chin Intern Med，2024，38（11）：99-102.
  37. 37.
    DU J C，XIAO H，DU G J.Systematic evaluation and therapeutic mechanism of Xiaochaihu decoction in treating gastritis［J］.J Henan Univ（Nat Sci），2020，50（5）：535-550.
  38. 38.
    WANG J X，WANG S H，MAO X，et al.Zuojin pill attenuates Helicobacter pylori-induced chronic atrophic gastritis in rats and improves gastric epithelial cells function in GES-1 cells［J］.J Ethnopharmacol，2021，285：114855.
  39. 39.
    CHEN L，HE T，WANG R，et al.Integrated approaches revealed the therapeutic mechanisms of Zuojin pill against gastric mucosa injury in a rat model with chronic atrophic gastritis［J］.Drug Des Devel Ther，2024，18：1651-1672.
  40. 40.
    DUAN Y Q，GONG Z H，WANG L Y，et al.Effects of Xiangsha Liujunzi decoction on PI3K signaling pathway correlation factor expression in gastric tissue of rats with chronic atrophic gastritis［J］.Chin J Inf Tradit Chin Med，2020，27（3）：33-38.
  41. 41.
    LIU Y Y，LI H，DING T T，et al.Effect of modified Shashen Maidong decoction on rats with chronic atrophic gastritis by regulating EGFR/MAPK signaling pathway［J］.Jilin J Chin Med，2022，42（7）：812-816.
  42. 42.
    LIU Y T，LI H，DING T T，et al.Effects of modified Shashen Maidong decoction in rats with chronic atrophic gastritis based on TGF-β1/PI3K/Akt pathway［J］.J Clin Med Pract，2023，27（14）：82-89.
  43. 43.
    YIN M M，SUI J L，WANG M L，et al.Morodan concentrated pills for the treatment of chronicatrophic gastritis and its mechanism of action［J］.Mod Chin Med，2024，44（2）：98-109.
  44. 44.
    TANG X D，FANG J Y.Clinical application guide of traditional Chinese patent medicines and simple preparations in the treatment of chronic gastritis［J］.Chin J Integr Tradit West Med，2021，41（2）：157-163.
  45. 45.
    CHEN Z Y.Effect of Moluodan combined with quadruple therapy in the treatment of helicobacter pylori-related chronic atrophic gastritis［J］.Chin Foreign Med Res，2024，22（20）：131-135.
  46. 46.
    YI Z R，LIN Y L，WANG Y J，et al.Effect of Elian granule on autophagy and PI3K/Akt/mTOR signaling pathway in gastric tissue of rats with gastric cancer［J］.Chin J Exp Tradit Med Form，2021，27（22）：84-91.
  47. 47.
    CHEN Z H，AN J，WEI Y，et al.The effect of Xiaopi granules on miR-21-PTEN-PI3K/Akt signaling pathway in gastric mucosal tissue of rats with gastric precancerous lesions model［J］.J Tradit Chin Med，2020，61（18）：1628-1632.
  48. 48.
    XU Y L，ZHU F Y，XU S.The effect of modified formula of "Lewei Yin" on gastric mucosal lesions and related inflammatory factors in chronic atrophic gastritis model mice［J］.Zhejiang J Tradit Chin Med，2020，55（2）：93-94.
  49. 49.
    ZHU F Y，XU S，XIE G Q.Effects of modified Lewei decoction on the co-regulated cytokines of NF-κB and STAT3 in precancerous lesions of gastric cancer［J］.Chin J Tradit Chin Med Pharm，2018，33（1）：350-352.
  50. 50.
    YE Y，LI C L，QU M Q，et al.Modified Leweiyin formula regulates glycolysis through PI3K/Akt/mTOR signaling pathway in treatment of chronic atrophic gastritis［J］.Chin J Integr Tradit West Med，2024，45（2）：190-197.
  51. 51.
    HUANG X M，FAN X Y，LU M.Protective effect of Qiling prescription on rats with chronic atrophic gastritis combined with gastric intestinal metaplasia via PI3K/Akt pathway［J］.Chin J Exp Tradit Med Form，2024，30（22）：79-86.
  52. 52.
    YAN Z P，XU T T，AN Z T，et al.Effects of Jianpi Yiqi formula on expression of PI3K-Akt signaling pathway in gastric tissue of rats with chronic atrophic gastritis［J］.Chin J Tradit Chin Med Pharm，2019，34（10）：4800-4804.
  53. 53.
    WANG S P，LI D G，MA X F，et al.Review of the treatment of chronic atrophic gastritis gastric precancerous lesions guided by turbid toxin theory in recent 20 years［J］.Chin J Tradit Chin Med Pharm，2024，39（8）：4416-4418.
  54. 54.
    GENG J Z，WANG Q M，LIU Z M，et al.Exploring the experience of Chinese medical master LIU Zhiming in treating chronic gastritis based on the Xinkai Kujiang method［J］.Lishizhen Med Mater Med Res，2025，36（6）：1141-1143.
  55. 55.
    WANG J，SUN M W，HOU J J.Summary of professor JIANG Shumin 's experience in treating chronic atrophic gastritis［J/OL］.Liaoning J Tradit Chin Med，2025..
  56. 56.
    YIN L M，YUAN J，CHEN K，et al.Jiedu Huoxue prescription affects plaque stability in ApoE-/-atherosclerosis mice by modulating PI3K/Akt/mTOR signaling pathway［J］.Chin J Exp Tradit Med Form，2023，29（12）：112-120.

続きを読む

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website